



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/896,226	06/29/2001	Eric J. Benjamin	AM100155	9422
25291	7590	02/07/2006	EXAMINER KANTAMNENI, SHOBHA	
WYETH PATENT LAW GROUP 5 GIRALDA FARMS MADISON, NJ 07940			ART UNIT 1617	PAPER NUMBER
DATE MAILED: 02/07/2006				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/896,226	Applicant(s) BENJAMIN ET AL.	
	Examiner Shobha Kantamneni	Art Unit 1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 17 November 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 32-42 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☒ Claim(s) NONE is/are allowed.
- 6) ☒ Claim(s) 32-42 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

This Office Action is a response to Applicant's response filed on November 17, 2005 wherein no amendment is filed, i.e., no claims are amended, cancelled, or newly submitted.

Currently claims 32-42 are pending, and examined herein.

The rejection of claims 32-42 under the judicially created doctrine of obviousness type double patenting as being unpatentable over claim 1 of U.S. Patent No. 6,479,535 is MAINTAINED. Note that applicants will file a terminal disclaimer upon indication of allowable claims.

In view of new ground(s) of rejection(s), the claim rejections under 35 U.S.C. 103 (a), of record in the previous Office Action dated 08/18/2005 are herein withdrawn.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 32-42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Raveendranath et al. (WO 9919293, PTO-1449 submitted September 18, 2001), in view of Sawicka (Pharmazie 1991, vol.46 page 519-521, PTO-1449 submitted September 28, 2001), and further in view of Gibson et al. (US 5,811,120, PTO-892).

Art Unit: 1617

Raveendranath et al. disclose a pharmaceutical composition comprising the instant particular compound, 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxyl)-benzyl]-1H-indol-5-ol (see its structure at the bottom of page 37 and Example 15 at page 40 and a pharmaceutically acceptable carrier or excipients to be administered to a mammal; the testing results for the composition comprising Example 15 at page 42, 44, 46, 47 are also disclosed. Raveendranath et al. also disclose that the effective amount of the compound to be administered for treating diseases therein is a dose of from about 0.1 mg/day to about 1,000 mg/day; preferably, administration will be from about 50 mg/day to about 600 mg/day in a single dose or in two or more divided doses (see page 29, lines 23-25).

In particular, Raveendranath et al. teach that: "Oral formulations containing the active compounds of this invention may comprise any conventionally used oral forms including tablets, capsules, buccal, forms, troches, lozenges and oral liquids, suspensions or solutions. Capsules may contain mixtures of the active compound(s) with inert fillers and/or diluents such as the pharmaceutically acceptable starches (e.g. corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums. etc. Useful tablet formulations may be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, microcrystalline cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidone, gelatin, alginic acid, acacia gum,

Art Unit: 1617

xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, dextrin, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dry starches and powdered sugar. Oral formulations herein may utilize standard delay or time release formulations to alter the absorption of the active compounds." (emphases added, see page 30, lines 1-19).

Raveendranath et al. does not expressly disclose the pharmaceutical composition herein further comprising an antioxidant.

Raveendranath et al. do not expressly disclose the specific range of amounts of a filler and disintegrant components, a wetting agent, a lubricant, and a glidant in a pharmaceutical composition herein.

Sawicka teaches that adding an antioxidant to a pharmaceutical composition is well known in the art and the stability of a pharmaceutical formulation may be increase by antioxidant addition. See abstract and the entire article.

Gibson et al. (US 5,811,120, PTO-892) teaches a pharmaceutical composition and a process for making such composition comprising a poorly soluble pharmaceutical agent, raloxifene hydrochloride salt. It is also taught that poor or low water solubility, and hydrophobicity of raloxifene salt results in limited bioavailability, optimum, and consistent absorption. See abstract; column 1, lines 55-64. The pharmaceutical composition also comprises surfactant or wetting agents, disintegrants, lubricants, glidants, and water soluble diluents. Surfactants or wetting agents such as sodium laurylsulfate, cholic acid, polyoxyethylene sorbitan fatty acids esters, etc are disclosed. See column 3 line 60-column 4, line 2; see Formulation 6, wherein 2 % of sodium lauryl

Art Unit: 1617

sulfate is present. Disintegrants such as starches, clays, celluloses, sodium starch glycolate are disclosed. See column 4, lines 8-15; see Formulation 9, wherein 5.8 % of sodium starch glycolate is present. Lubricants or glidants such as 0.4 % magnesium stearate (see Formulation 9, column 8), colloidal silicon dioxide, microcrystalline cellulose, sodium lauryl sulfate etc. are taught. See column 4, lines 16-26. The composition also contains water soluble diluents such as about 37 % lactose, sucrose etc. See column 4, lines 3-8; see Formulation 6. The compositions for oral administration may be in the form of tablets, capsules. See Formulations 1-15.

It would have been obvious to a person of ordinary skill in the art at the time of invention to add an antioxidant to the composition of Raveendranath et al. One of ordinary skill in the art at the time of invention would have been motivated to add an antioxidant to the pharmaceutical composition of Raveendranath et al. with the expectation of increasing the stability of the composition since adding an antioxidant to a pharmaceutical composition to increase stability is well known in the pharmaceutical art.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to determine the specific range of amounts of a filler and disintegrant components, a wetting agent, a lubricant, and a glidant in a pharmaceutical composition herein.

One having ordinary skill in the art at the time the invention was made would have been motivated to determine the specific range of amounts of a filler, disintegrant components, a wetting agent, a lubricant, and a glidant in a pharmaceutical composition

Art Unit: 1617

with the expectation of obtaining a pharmaceutical composition with increased solubility, and optimum bioavailability of 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxyl)-benzyl]-1H-indol-5-ol because Gibson teaches such specific range of amounts of a filler, disintergrant components, a wetting agent, a lubricant, and a glidant in a pharmaceutical composition comprising low soluble, hydrophobic compound.

Further, the determination and the optimization of amounts of known active agents, excipients such as a known filler, known disintergrant components, a known wetting agent, a known lubricant, and a known glidant in a pharmaceutical composition are considered conventional to an ordinary skilled artisan in pharmaceutical science, involving merely routine skill in the art.

It has been held that it is within the skill in the art to select optimal parameters, such as amounts of ingredients, in a composition in order to achieve a beneficial effect. See *In re Boesch*, 205 USPQ 215 (CCPA 1980).

Thus the claimed invention as a whole is clearly *prima facie* obvious over the combined teachings of the prior art.

Claims 32-42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Miller et al. (EP 802183, PTO-1449 submitted June 10, 2005), in view of Sawicka (Pharmazie 1991, vol.46 page 519-521, PTO-1449 submitted September 28, 2001), and further in view of Gibson et al. (US 5,811,120, PTO-892).

Miller et al. disclose a pharmaceutical composition comprising the instant particular compound, 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxyl)-

Art Unit: 1617

benzyl]-1H-indol-5-ol (see its structure Example No. **97**, at the bottom of page 8; page 37-38; page 41, line 55) or 1-[4-(2-Azepan-yl-ethoxyl-benzyl)-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol (see its structure Example No. **98**: page 37-38; page 44, lines 17-27) and a pharmaceutically acceptable carrier or excipients to be administered to a mammal. The testing results for the composition comprising Example **97** and **98** at page 64, 72, 74, 46, 47 are also disclosed. Miller et al. also disclose that the effective amount of the compound to be administered for treating diseases therein is a dose of from about 0.1 mg/day to about 1,000 mg/day; preferably, administration will be from about 50 mg/day to about 600 mg/day in a single dose or in two or more divided doses (see page 13, lines 16-18).

In particular, Miller et al. teach that:

"Oral formulations containing the active compounds of this invention may comprise any conventionally used oral forms including tablets, capsules, buccal, forms, troches, lozenges and oral liquids, suspensions or solutions. Capsules may contain mixtures of the active compound(s) with inert fillers and/or diluents such as the pharmaceutically acceptable starches (e.g. corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums. etc. Useful tablet formulations may be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, microcrystalline cellulose,

Art Unit: 1617

carboxymethylcellulose calcium, polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, dextrin, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dry starches and powdered sugar. Oral formulations herein may be utilize standard delay or time release formulations to alter the absorption of the active compounds." (emphases added, see page 13, lines 25-37).

Miller et al. does not expressly disclose the pharmaceutical composition herein further comprising an antioxidant.

Miller et al. do not expressly disclose the specific range of amounts of a filler, disintegrant components, a wetting agent, a lubricant, and a glidant in a pharmaceutical composition herein.

Sawicka teaches that adding an antioxidant to a pharmaceutical composition is well known in the art and the stability of a pharmaceutical formulation may be increase by antioxidant addition. See abstract and the entire article.

Gibson et al. (US 5,811,120, PTO-892) teaches a pharmaceutical composition and a process for making such composition comprising a poorly soluble pharmaceutical agent, raloxifene hydrochloride salt. It is also taught that poor or low water solubility, and hydrophobicity of raloxifene salt results in limited bioavailability, optimum, and consistent absorption. See abstract; column 1, lines 55-64. The pharmaceutical composition also comprises surfactant or wetting agents, disintegrants, lubricants, glidants, and water soluble diluents. Surfactants or wetting agents such as sodium laurylsulfate, cholic acid, polyoxyethylene sorbitan fatty acids esters, etc are disclosed.

Art Unit: 1617

See column 3 line 60-column 4, line 2; see Formulation 6, wherein 2 % of sodium lauryl sulfate is present. Disintegrants such as starches, clays, celluloses, sodium starch glycolate are disclosed. See column 4, lines 8-15; see Formulation 9, wherein 5.8 % of sodium starch glycolate is present. Lubricants or glidants such as 0.4 % magnesium stearate (see Formulation 9, column 8), colloidal silicon dioxide, microcrystalline cellulose, sodium lauryl sulfate etc. are taught. See column 4, lines 16-26. The composition also contains water soluble diluents such as about 37 % lactose, sucrose etc. See column 4, lines 3-8; see Formulation 6. The compositions for oral administration may be in the form of tablets, capsules. See Formulations 1-15.

It would have been obvious to a person of ordinary skill in the art at the time of invention to add an antioxidant to the composition of Raveendranath et al. One of ordinary skill in the art at the time of invention would have been motivated to add an antioxidant to the pharmaceutical composition of Raveendranath et al. with the expectation of increasing the stability of the composition since adding an antioxidant to a pharmaceutical composition to increase stability is well known in the pharmaceutical art.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to determine the specific range of amounts of a filler and disintegrant components, a wetting agent, a lubricant, and a glidant in a pharmaceutical composition herein.

One having ordinary skill in the art at the time the invention was made would have been motivated to determine the specific range of amounts of a filler, disintegrant

Art Unit: 1617

components, a wetting agent, a lubricant, and a glidant in a pharmaceutical composition with the expectation of obtaining a pharmaceutical composition with increased solubility, and optimum bioavailability of 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxyl)-benzyl]-1H-indol-5-ol because Gibson teaches such specific range of amounts of a filler, disintergrant components, a wetting agent, a lubricant, and a glidant in a pharmaceutical composition comprising low soluble, hydrophobic compound.

Further, the determination and the optimization of amounts of known active agents, excipients such as a known filler, known disintergrant components, a known wetting agent, a known lubricant, and a known glidant in a pharmaceutical composition are considered conventional to an ordinary skilled artisan in pharmaceutical science, involving merely routine skill in the art.

It has been held that it is within the skill in the art to select optimal parameters, such as amounts of ingredients, in a composition in order to achieve a beneficial effect. See *In re Boesch*, 205 USPQ 215 (CCPA 1980).

Thus the claimed invention as a whole is clearly *prima facie* obvious over the combined teachings of the prior art.

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shobha Kantamneni whose telephone number is 571-272-2930. The examiner can normally be reached on Monday-Friday, 8am-5pm.

Art Unit: 1617

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Shobha Kantamneni, Ph.D
Patent Examiner
Art Unit : 1617

SHENGJUNWANG
PRIMARY EXAMINER

